Background
Advanced NET is a rare, progressive and fatal malignancy, and often diagnosed at an advanced stage (~50% of newly diagnosed patients). 1 The incidence of NETs has increased from 2.48 per 100,000 in 1994 to 5.86 per 100,000 persons in 2009 in Ontario, Canada. 2 It is estimated that 72% (range 60-85%) of GI and lung NETs are nonfunctional. [4] [5] Non-functioning NETs are generally asymptomatic and often go undiagnosed until the disease is advanced.
The median survival for advanced NET patients is between 5 and 55 months, depending on the tumor grade and stage, with an estimated 65% of patients dying within the first 5 years following diagnosis. 1 Majority of NET patients report decreased quality of life resulting in lifestyle changes. 3 Current available treatment options for advanced, non-functional, progressive GI/lung NETs include surgical resection, cytotoxic chemotherapy, peptide receptor radiation therapy (PRRT), interferon, somatostatin analogues (SSAs) and molecularly-targeted therapies. [6] [7] [8] [9] [10] [11] Though currently available systemic therapies have demonstrated some clinically efficacy and safety, there is lack of evidence on quality of life outcome measures.
RADIANT-4 trial demonstrated the clinical benefits of everolimus plus best supportive care (BSC) versus BSC alone in patients with advanced progressive, non-functional neuroendocrine tumors (NET) of the GI or lung origin.
Afinitor®(everolimus) was approved May 17, 2016 by Health Canada for the treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal or lung origin in adults with progressive disease. AFINITOR® is also approved for the treatment of well-or moderately differentiated neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease that has progressed within the last 12 months.
Objective
To evaluate the cost-effectiveness of everolimus plus BSC versus BSC* alone in advanced (unresectable or metastatic), progressive non-functional GI/lung NET patients in Canada, based on the results of the phase 3 randomized controlled trial (RADIANT-4).
Methods
An Excel-based partitioned survival model was developed to compare everolimus plus BSC versus BSC alone in advanced (unresectable or metastatic), progressive non-functional GI/lung NET patients.
Patients were assumed to be in three mutually exclusive health states: Stable Disease (SD), Disease Progression(PD) and Death ( Figure 1 ).
The proportion of patients in each health state, over the course of time, was estimated using survival functions for PFS and OS.
Figure 1. Partitioned Survival Model Schema
Post-progression survival (PPS) was defined as to be the difference between OS and PFS.
Half cycle correction was applied.
Extrapolation post month 27 of the OS curves from RADIANT-4 for the BSC arm was generated by applying a HR of 0.73 (HR = 0.73, 95% CI: 0.48, 1. 11) derived from the RADIANT-4 trial data to the OS curve in the everolimus arm plus BSC.
Clinical data inputs were obtained from the RADIANT-4 trial.
Relative dose intensity (RDI) for everolimus was assumed to be 1.00.
Health utilities were mapped from quality of life data retrieved from the RADIANT-4 trial. Disutility was not considered as it was assumed that quality of life data from the trial would inherently consider the effect of adverse events on a patient's quality of life.
Tunnel states were included for adverse events (AE) to derive AE specific costs.
Expected costs of post study anti-cancer therapy were estimated based on RADIANT-4 trial.
Costs and quality of life were assumed to be conditioned on treatment and expected time in these disease states.
*Best supportive care included all care provided to patients deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics.
Costs and efficacy outcomes (QALYs/LYs) were discounted 5% annually over a 10 year time horizon.
Costs of AE's were obtained from Ontario Case Costing Initiative; other direct and indirect costs were obtained from official reimbursement lists from Ontario and other published sources.
Resource utilization data were derived from a Canadian physician survey. Drug costs were extracted from IMSHealth™ Delta PA database.
Deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of the parameter estimates.
• Cost-effectiveness acceptability curves (CEACs) were constructed to determine the probability in which everolimus plus BSC was cost-effective relative to BSC alone. • A tornado diagram was generated for one way sensitivity analysis to assess the impact of each parameter over specified ranges.
Analyses were conducted from the Canadian societal perspective. 
Results

Summary
This is the first study to assess the cost-effectiveness of everolimus plus BSC vs BSC alone in patients with non-functional patients with advanced neuroendocrine tumors of GI or lung origin.
Everolimus yields 0.616 more discounted QALYs than BSC at an incremental cost of CAD$89,795 (ICER= CAD$145,670).
Based on a CAD$150,000/QALY willingness to pay threshold, there is a 52% probability of everolimus being cost-effective vs. BSC alone.
One way sensitivity analysis demonstrated that the results are most sensitive to: 
Conclusions
Everolimus is a treatment option in patients with advanced, non-functional, progressive neuroendocrine tumors of GI or lung origin.
Based on the current economic evaluation, everolimus is predicted to offer clinical benefits compared with best supportive care, with an estimated incremental cost-effectiveness ratio of CAD$145,670/QALY or $109, 116/LY in the base case.
